Denali Therapeutics Inc. (DNLI)
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
3 Biotech Stocks That Could Double In 2026
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the market, as growth in other sectors of the economy have led to valuations that now look more elevated than the biotech sector (in many cases).
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
3 Biotech Stocks With Major 2026 Catalysts
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Denali Enters Into a $275M Funding Deal With Royalty Pharma
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali: Regulatory Delay Is A Strategic Opportunity
Denali Therapeutics (DNLI) is transitioning from a clinical-stage to a commercial-stage biotech, leveraging its innovative blood-brain barrier Transport Vehicle platform. DNLI's financials reflect increased investment in manufacturing and commercialization, with sufficient cash runway (~1.5 years) to support upcoming product launches. Tividenofusp Alfa (DNL310) for MPS II is the lead candidate, with FDA review delayed to April 2026 but no major clinical concerns cited by regulators.
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript
Denali Therapeutics Inc. ( DNLI ) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Ryan Watts - Co-Founder, President, CEO & Director Alexander Schuth - Co-Founder, CFO, COO & Secretary Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division Okay. We're going to get started with our next session.
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Denali Therapeutics Inc. (NASDAQ:DNLI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Ryan Watts - Co-Founder, President, CEO & Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. mid-cap biotech equity research at the firm.
